PMID- 36448591
OWN - NLM
STAT- MEDLINE
DCOM- 20221201
LR  - 20221215
IS  - 1753-4666 (Electronic)
IS  - 1753-4658 (Print)
IS  - 1753-4658 (Linking)
VI  - 16
DP  - 2022 Jan-Dec
TI  - Association of dipeptidyl peptidase-4 inhibitor use and the risk of asthma 
      development among type 2 diabetes patients.
PG  - 17534666221135320
LID - 10.1177/17534666221135320 [doi]
LID - 17534666221135320
AB  - BACKGROUND: Numerous studies have shown that dipeptidyl peptidase-4 inhibitors 
      (DPP-4i) may regulate immunological pathways implicated in asthma. The 
      association between DPP-4i use and risk of asthma development is limited, 
      however. AIM: We aimed to evaluate if DPP-4i treatment in individuals with type 2 
      diabetes mellitus (T2DM) is associated with a lower risk and severity of asthma. 
      METHODS: We performed a population-based retrospective cohort study using the 
      Longitudinal National Health Insurance Research database between 2008 and 2015. 
      After one-to-four propensity score matching from 1,914,201 patients with defined 
      criteria, we enrolled 3001 patients who were on DPP-4i (DPP-4i group) for a 
      diagnosis of T2DM but without a diagnosis of asthma for further analysis. Cox 
      proportional hazards regression analysis was performed to estimate and compare 
      the risk of developing and severity of asthma, including no acute exacerbations 
      event (No-AE), acute exacerbations (AEs), status asthmaticus (Status), and 
      required endotracheal intubation (ET-tube intubated), between the two groups. 
      RESULTS: The participants had a mean age of 66.05 +/- 17.23 years and the mean 
      follow-up time was 4.96 +/- 4.39 years. The risk of asthma development was 
      significantly lower in the DPP-4i group than in the non-DPP-4i group [adjusted 
      hazard ratio (HR) = 0.65; 95% confidence interval (CI) = 0.29-0.83; p < 0.001], 
      with a class effect. This trend was observed for severity of asthma as No-AE 
      (HR = 0.55; 95% CI = 0.24-0.70; p < 0.001), AE (HR = 0.57; 95% CI = 0.26-0.73; 
      p < 0.001), and Status (HR = 0.78; 95% CI = 0.35-0.99; p = 0.047), but not in 
      ET-tube intubated cases (HR = 0.96; 95% CI = 0.43-1.22; p = 0.258). CONCLUSION: 
      The use of DPP-4i decreased the risk and severity of asthma with a class effect 
      among No-AE, AE, status of asthma events, but not in ET-tube intubated events. 
      Our report suggests that DPP-4i may play a role in attenuating the impact of 
      asthma on incidence in the future and on more severe forms of disease 
      exacerbation in T2DM patients.
FAU - Li, Peng-Fei
AU  - Li PF
AUID- ORCID: 0000-0002-3044-7976
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Tri-Service General Hospital, National Defense Medical School, Taipei.
AD  - Graduate Institute of Applied Science and Engineering, Fu Jen Catholic 
      University, New Taipei.
FAU - Chung, Chi-Hsiang
AU  - Chung CH
AD  - School of Public Health, National Defense Medical Center, Taipei.
AD  - Taiwanese Injury Prevention and Safety Promotion Association, Taipei.
FAU - Liu, Jhih-Syuan
AU  - Liu JS
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Tri-Service General Hospital, National Defense Medical School, Taipei.
FAU - Lu, Chieh-Hua
AU  - Lu CH
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Tri-Service General Hospital, National Defense Medical School, Taipei.
AD  - Department of Medical Research, Tri-Service General Hospital, National Defense 
      Medical Center, Taipei.
FAU - Su, Sheng-Chiang
AU  - Su SC
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Tri-Service General Hospital, National Defense Medical School, Taipei.
FAU - Kuo, Feng-Chih
AU  - Kuo FC
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Tri-Service General Hospital, National Defense Medical School, Taipei.
FAU - Ho, Li-Ju
AU  - Ho LJ
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Tri-Service General Hospital, National Defense Medical School, Taipei.
FAU - Chen, Kuan-Chan
AU  - Chen KC
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Tri-Service General Hospital, National Defense Medical School, Taipei.
FAU - Su, Yu-Te
AU  - Su YT
AD  - Department of Emergency Medicine, Tri-Service General Hospital, National Defense 
      Medical School, Taipei.
FAU - Chu, Nain-Feng
AU  - Chu NF
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Tri-Service General Hospital, National Defense Medical School, Taipei.
FAU - Lee, Chien-Hsing
AU  - Lee CH
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Tri-Service General Hospital, National Defense Medical School, Taipei.
AD  - Department of Medical Research, Tri-Service General Hospital, National Defense 
      Medical Center, Taipei.
FAU - Hsieh, Chang-Hsun
AU  - Hsieh CH
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Tri-Service General Hospital, National Defense Medical School, Taipei.
FAU - Hung, Yi-Jen
AU  - Hung YJ
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      Tri-Service General Hospital, National Defense Medical School, Taipei.
FAU - Lin, Fu-Huang
AU  - Lin FH
AD  - School of Public Health, National Defense Medical Center, Taipei.
FAU - Chien, Wu-Chien
AU  - Chien WC
AD  - School of Public Health, National Defense Medical Center, Taipei.
AD  - Taiwanese Injury Prevention and Safety Promotion Association, Taipei.
AD  - Department of Medical Research, Tri-Service General Hospital, National Defense 
      Medical Center 114, Taipei.
FAU - Liang, Yao-Jen
AU  - Liang YJ
AD  - Graduate Institute of Applied Science and Engineering and Institute of Life 
      Science, Fu Jen Catholic University, Number 510, Zhong-Zheng Road, Xin-Zhuang, 
      New Taipei 242.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Ther Adv Respir Dis
JT  - Therapeutic advances in respiratory disease
JID - 101316317
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Antiviral Agents)
RN  - EC 3.4.14.- (Dipeptidyl-Peptidases and Tripeptidyl-Peptidases)
SB  - IM
MH  - Humans
MH  - Middle Aged
MH  - Aged
MH  - Aged, 80 and over
MH  - *Dipeptidyl-Peptidase IV Inhibitors/adverse effects
MH  - *Diabetes Mellitus, Type 2/diagnosis/drug therapy
MH  - Retrospective Studies
MH  - Antiviral Agents
MH  - *Asthma/diagnosis/drug therapy/epidemiology
MH  - Dipeptidyl-Peptidases and Tripeptidyl-Peptidases
PMC - PMC9716455
OTO - NOTNLM
OT  - acute exacerbation
OT  - asthma
OT  - dipeptidyl peptidase-4 inhibitors
OT  - type 2 diabetes mellitus
COIS- The authors declared no potential conflicts of interest with respect to the 
      research, authorship, and/or publication of this article.
EDAT- 2022/12/01 06:00
MHDA- 2022/12/02 06:00
PMCR- 2022/11/30
CRDT- 2022/11/30 06:33
PHST- 2022/11/30 06:33 [entrez]
PHST- 2022/12/01 06:00 [pubmed]
PHST- 2022/12/02 06:00 [medline]
PHST- 2022/11/30 00:00 [pmc-release]
AID - 10.1177_17534666221135320 [pii]
AID - 10.1177/17534666221135320 [doi]
PST - ppublish
SO  - Ther Adv Respir Dis. 2022 Jan-Dec;16:17534666221135320. doi: 
      10.1177/17534666221135320.